Innovative Product Somahlution offers DuraGraft, a specialized vascular graft treatment that enhances clinical outcomes by reducing graft failure complications, positioning the company as a key player in advanced vascular healthcare solutions.
Strategic Acquisition The recent acquisition by Marizyme in December 2020 provides enhanced resources and a broader distribution network, offering opportunities for upselling existing products and expanding into new markets.
Market Focus Operating within the biotechnology research industry with a niche focus on cardiovascular graft treatments, Somahlution presents targeted sales potential into hospitals, surgical centers, and vascular clinics seeking innovative graft solutions.
Financial Window With annual revenues estimated between $10M and $25M, there is significant growth potential, especially through strategic partnerships and expanding sales efforts within cardiovascular and surgical sectors.
Technology Leverage Utilizing modern web technologies and a strong digital presence, Somahlution is well-positioned for digital outreach, educational campaigns, and building relationships with healthcare providers and decision-makers.
$1B$10B
$1B$10B
$1M$10M
$1B$10B
$1B$10B
$10B
$10BSomahlution: DuraGraft Vascular Graft Treatment Improves Outcomes in Coronary Artery Bypass Grafting uses 8 technology products and services including Varnish, WordPress, MySQL, and more. Explore Somahlution: DuraGraft Vascular Graft Treatment Improves Outcomes in Coronary Artery Bypass Grafting's tech stack below.
| Somahlution: DuraGraft Vascular Graft Treatment Improves Outcomes in Coronary Artery Bypass Grafting Email Formats | Percentage |
| First.Last@somahlution.com | 38% |
| FirstL@somahlution.com | 17% |
| First@somahlution.com | 7% |
| First.Last@somahlution.com | 38% |
Biotechnology ResearchFlorida, United States11-50 Employees
The DuraGraft® Difference: DuraGraft is a vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure. Not Available In The United States.
Company Overview
Funding & FinancialsSomahlution: DuraGraft Vascular Graft Treatment Improves Outcomes in Coronary Artery Bypass Grafting's revenue is estimated to be in the range of $10M$25M
Funding & FinancialsSomahlution: DuraGraft Vascular Graft Treatment Improves Outcomes in Coronary Artery Bypass Grafting's revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com